Thus, despite some promising results, it is evident that further investigation into the molecular mechanisms underpinning AR and PI3K-AKT-mTOR pathway crosstalk in prostate cancer is required to improve patient stratification and to discover new therapeutic approaches and predictive biomarkers that can inform future clinical trial design. This evidence concerns the gene PIK3CG and prostate cancer.